Common Stock Compensation

9 Months Ended

Mar. 31, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

(10) Common Stock Compensation

Stock Option Activity Summary

The Company’s stock option activity for the nine months ended March 31, 2019, is as follows:

	Shares (in thousands)			Weighted Average Exercise Price
Outstanding at June 30, 2018		361		$	5.48
Granted		—			—
Exercised		(3	)		2.25
Canceled or expired		(33	)		3.45
Outstanding at March 31, 2019		325		$	5.71

The aggregate intrinsic value of options exercisable at March 31, 2019, was $17 thousand as the fair value of the Company’s common stock is more than the exercise prices of these options. The remaining share-based compensation expense of $193 thousand related to stock options will be recognized over a weighted-average period of 1.11 years.

The table below details the Company’s stock options outstanding as of March 31, 2019:

Range of exercise prices	Number Outstanding		Options Outstanding Weighted- Average Remaining Contractual Life (years)		Weighted- Average Exercise Price		Number Exercisable		Options Exercisable Weighted- Average Exercise Price
$1.60 – 3.55		70,500		3.23	$	3.39		70,500	$	3.39
$5.30 – 5.85		124,640		8.11		5.48		41,951		5.47
$6.00 – 8.35		130,000		5.65		7.19		86,000		6.59
$1.60 – 8.35		325,140		6.07	$	5.71		198,451	$	5.21

Compensation costs recognized related to stock option awards were $43 thousand and $93 thousand for the three months ended March 31, 2019, and 2018, respectively, and $128 thousand and $226 thousand for the nine months ended March 31, 2019, and 2018, respectively.

Restricted Stock

The Company’s restricted stock activity for the nine months ended March 31, 2019, is as follows:

	Shares (in thousands)			Weighted Average Grant-Date Fair Value
Outstanding at June 30, 2018		28		$	10.16
Granted		199			3.40
Vested		(4	)		8.86
Canceled or expired		(5	)		9.58
Outstanding at March 31, 2019		218		$	4.03

Stock compensation expenses related to restricted stock were $64 thousand and $53 thousand for the three months ended March 31, 2019, and 2018, respectively, and $77 thousand and $161 thousand for the nine months ended March 31, 2019, and 2018, respectively. The remaining share-based compensation expense of $626 thousand related to restricted stock awards granted will be recognized over a weighted-average period of 2.67 years.